OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016

Via: OncoMed

REDWOOD CITY, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting.  All three presentations support ongoing clinical trials:  anti-RSPO3  in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab  in a Phase 1b trial in pancreatic cancer; and demcizumab  in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).

Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=965947